###begin article-title 0
###xml 37 43 <span type="species:ncbi:10090">Murine</span>
Splenectomy Normalizes Hematocrit in Murine Polycythemia Vera
###end article-title 0
###begin p 1
Conceived and designed the experiments: ESB. Performed the experiments: JRM AM MA SZ YW. Analyzed the data: JRM AM SZ ESB. Contributed reagents/materials/analysis tools: JRM AM YW DG AD. Wrote the paper: JRM ESB.
###end p 1
###begin p 2
Current address: Section in Endocrinology, Diabetes and Nutrition, Boston University School of Medicine, Boston, Massachusetts, United States of America
###end p 2
###begin p 3
###xml 223 227 223 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617</sup>
###xml 614 619 614 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 710 715 710 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 805 809 805 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617</sup>
###xml 1285 1290 1285 1290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 319 327 <span type="species:ncbi:9606">patients</span>
###xml 429 434 <span type="species:ncbi:9606">human</span>
###xml 594 600 <span type="species:ncbi:10090">murine</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
###xml 737 741 <span type="species:ncbi:10090">mice</span>
###xml 858 862 <span type="species:ncbi:10090">mice</span>
###xml 1273 1279 <span type="species:ncbi:10090">murine</span>
Splenic enlargement (splenomegaly) develops in numerous disease states, although a specific pathogenic role for the spleen has rarely been described. In polycythemia vera (PV), an activating mutation in Janus kinase 2 (JAK2V617) induces splenomegaly and an increase in hematocrit. Splenectomy is sparingly performed in patients with PV, however, due to surgical complications. Thus, the role of the spleen in the pathogenesis of human PV remains unknown. We specifically tested the role of the spleen in the pathogenesis of PV by performing either sham (SH) or splenectomy (SPL) surgeries in a murine model of JAK2V617F-driven PV. Compared to SH-operated mice, which rapidly develop high hematocrits after JAK2V617F transplantation, SPL mice completely fail to develop this phenotype. Disease burden (JAK2V617) is equivalent in the bone marrow of SH and SPL mice, however, and both groups develop fibrosis and osteosclerosis. If SPL is performed after PV is established, hematocrit rapidly declines to normal even though myelofibrosis and osteosclerosis again develop independently in the bone marrow. In contrast, SPL only blunts hematocrit elevation in secondary, erythropoietin-induced polycythemia. We conclude that the spleen is required for an elevated hematocrit in murine, JAK2V617F-driven PV, and propose that this phenotype of PV may require a specific interaction between mutant cells and the spleen.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 820 823 820 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-1">[1]</xref>
###xml 825 828 825 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Mesa1">[2]</xref>
###xml 990 993 990 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Gilbert1">[3]</xref>
###xml 994 997 994 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Cunningham1">[5]</xref>
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 126 131 <span type="species:ncbi:9606">human</span>
###xml 664 672 <span type="species:ncbi:9606">patients</span>
The mammalian spleen, an organ that is not required for adult human life, has rarely been proposed to play a specific role in human disease. That is, despite pathologic enlargement (splenomegaly) in numerous conditions, splenectomy rarely results in reversal of the underlying disease process. Splenomegaly often reflects an expansion of cellular proliferation outside of the bone marrow compartment, and is called extramedullary hematopoiesis (EMH). This process can occur not only in spleen, but also in liver, kidney and lymph nodes. Whether EMH plays a required or permissive role in myeloproliferative disorders (MPDs) is unknown. Splenomegaly is observed in patients with the Philadelphia chromosome positive MPD chronic myelogenous leukemia (CML), for example, but splenectomy fails to affect disease progression [1], [2]. On the other hand, the role of the spleen in the progression of another MPD, polycythemia vera (PV), has not been tested due to frequent surgical complications [3]-[5]. The pathologic hallmark of PV is increased red blood cell mass (hematocrit) that is not mediated by the hormone erythropoietin (Epo). Thus, PV can be distinguished from secondary polycythemia by cell-autonomous proliferation or red blood cells.
###end p 5
###begin p 6
###xml 87 92 87 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 174 177 174 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-James1">[6]</xref>
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Zhao1">[10]</xref>
###xml 214 219 214 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 331 335 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Pardanani1">[11]</xref>
###xml 395 400 395 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 733 738 733 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 872 877 872 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 165 170 <span type="species:ncbi:9606">human</span>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 584 590 <span type="species:ncbi:10090">murine</span>
###xml 748 754 <span type="species:ncbi:10090">murine</span>
In 2005, an activating mutation in the nonreceptor tyrosine kinase Janus kinase 2 (JAK2V617F) was found to be present in the blood in more than 90% of patients with human PV [6]-[10]. Moreover, introduction of JAK2V617F into hematopoietic cells causes PV in mice, and inhibitors of Jak2 (Jak2i's) reduce hematocrit and spleen size [11]. We also observed that the efficacy of Jak2i's in such JAK2V617F-driven PV in mice is disproportionately associated with reduced disease burden entirely in spleen, with minimal effect in bone marrow (data not shown). Thus, efficacious treatment of murine PV with Jak2i's suggests that the spleen plays a critically important role in PV. In order to specifically test the role of the spleen in JAK2V617F -driven, murine PV, therefore, we performed surgery either prior to or following polycythemia-inducing bone marrow transplant of JAK2V617F cells, and characterized the resulting phenotype.
###end p 6
###begin title 7
Methods
###end title 7
###begin title 8
Animals
###end title 8
###begin p 9
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Six-week-old C57Bl/6 (B6) or Balb/c donor mice were obtained from Taconic Farms Inc. (Germantown, NY). The mice were maintained 5 to a cage in pathogen-free conditions. All animal studies were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC).
###end p 9
###begin title 10
Statistical Methods
###end title 10
###begin p 11
###xml 130 134 <span type="species:ncbi:10090">mice</span>
A Student's t-Test, assuming equal variance, was used to compare hematology parameters between sham (SH) and splenectomized (SPL) mice.
###end p 11
###begin title 12
Expression vectors and viral supernatants
###end title 12
###begin p 13
###xml 135 139 135 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Wernig1">[12]</xref>
###xml 4 10 <span type="species:ncbi:10090">murine</span>
###xml 220 226 <span type="species:ncbi:9913">bovine</span>
The murine Jak2 cDNA was cloned into the retroviral vector MSCV-IRES EGFP which was generously provided by Dr. Gilliland, as described [12]. We cultured 293T cells in Dulbecco modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS). Transient cotransfection of 293T cells by equal amounts of expression vectors and packaging plasmid (pCL-Eco, Imgenex, San Diego, CA) and generation of retroviral supernatant were performed using FuGENE (Roche, Nutley, NJ) according to the manufacturer's protocol. Viral supernatant was harvested after 48 hours and was used to transduce bone marrow or NIH 3T3 cells to assess viral titer.
###end p 13
###begin title 14
Jak2 V617F allele burden QPCR
###end title 14
###begin p 15
###xml 278 304 278 304 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CACATAGGAACTATTCAGAGTCTTTC</named-content>
###xml 317 340 317 340 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AGAATGTTCTCCTCTCCACAGTA</named-content>
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
###xml 61 66 <span type="species:ncbi:10090">mouse</span>
###xml 123 126 <span type="species:ncbi:9685">cat</span>
Genomic DNA from 30 ul of mouse peripheral blood or 10 mg of mouse tissue was purified by Qiagen tissue and blood DNA kit (cat #: 69506); 10 ng of genomic DNA was used for 10 ul QPCR reactions in 384-well plate format using ABI 7900HT Real-Time PCR system. Primers: Jak2cDNAF2: CACATAGGAACTATTCAGAGTCTTTC; Jak2MutR3: AGAATGTTCTCCTCTCCACAGTA (additional mutations were added to the primer to prevent amplification of unmatching sequences).
###end p 15
###begin title 16
###xml 55 59 <span type="species:ncbi:10090">mice</span>
Bone marrow transplantation and splenectomy surgery of mice
###end title 16
###begin p 17
###xml 275 276 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 740 741 736 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 816 817 808 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 920 921 906 907 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
###xml 353 357 <span type="species:ncbi:10090">mice</span>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
###xml 1116 1120 <span type="species:ncbi:10090">mice</span>
Murine BM transplantation experiments were performed as previously described (paper 1). Briefly, the viral titer was determined by transducing 3T3 cells with supernatant (plus polybrene, 10 microg/mL) and analyzed for the percentage of green fluorescent protein-positive (GFP+) cells by flow cytometry 2 days after transduction. C57Bl/6 or Balb/c donor mice were treated for 5 days with 5-fluorouracil (150 mg/kg, intraperitoneal injection). Bone marrow cells from donor mice were harvested by flushing femurs and tibias and were cultured for 24 hours in transplant medium (RPMI+10% FBS+6 ng/mL IL-3, 10 ng/mL IL-6, and 10 ng/mL stem cell factor). Cells were treated by spin infection with retroviral supernatants (1 mL supernatant per 4x106 cells, plus polybrene, plus HEPES 30 microL/4 mL) and centrifuged at 2500 g for 90 minutes at 30degreesC 24 hours before and on the day of transplantation. Whole BM cells (1.0x106) were resuspended in 200 uL Hanks balanced salt solution and were injected into lateral tail veins of lethally irradiated (2x5.5 Gy [550 rads]) C57Bl/6 or (2x4.5 Gy [450 rads]) Balb/c recipient mice.
###end p 17
###begin p 18
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 557 561 <span type="species:ncbi:10090">Mice</span>
Mice were anesthetized with isoflurane inhalation. After anesthesia, mice were surgically prepared by first shaving the incision site, followed by preparing the incision site with either Betadine/alcohol scrubs or chlorhexidene scrubs. A small incision was made in the left subcostal abdominal wall. The spleen will be exteriorized through the incision, and a splenectomy will be performed by placing ligatures around the splenic vasculature and removing the spleen. The incision will be closed in two layers using surgical suture material and wound clips. Mice were monitored for recovery from anesthesia and kept until wakeup at 37degreesC. Control group underwent a sham surgery (SH) and they were maintained in the same conditions.
###end p 18
###begin title 19
###xml 23 27 <span type="species:ncbi:10090">mice</span>
Analysis of disease in mice
###end title 19
###begin p 20
Peripheral blood was collected from the retro orbital cavity using EDTA glass capillary tubes and analyzed by using the Advia 120 Hematology System (Bayer Diagnostics) according to the manufacturer's instructions.
###end p 20
###begin title 21
Antibody staining and flow cytometry
###end title 21
###begin p 22
###xml 804 811 800 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Results</xref>
###xml 959 963 955 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Liu1">[13]</xref>
###xml 134 140 <span type="species:ncbi:9913">bovine</span>
###xml 363 368 <span type="species:ncbi:10090">mouse</span>
###xml 429 434 <span type="species:ncbi:10090">mouse</span>
Isolated bone marrow flushing by the femurs or spleen was strained through a 70-microm strainer in the presence of RPMI and 10% fetal bovine serum. Cells were blocked with Fc-block (BD Biosciences) for 15 minutes on ice, and stained with antibodies in Stain Buffer (BD Biosciences) for 30 minutes on ice. Antibodies used were allophycocyanin-alexa fluor 750 anti-mouse Ter-119 (eBioscience, San Diego, CA) and phycoerythrin anti-mouse CD71 (BD Biosciences). After washing, cells were resuspended in Stain Buffer containing Topo-3 (Invitrogen) to allow discrimination of nonviable cells. Flow cytometry was performed on a FACSLSRII cytometer (BD Biosciences, San Jose, CA). At least 10 000 events were acquired, and data were analyzed using FlowJo software (Tree Star, Stanford University, Stanford, CA). Results are presented as dot plots of viable cells selected on the basis of scatter and Topo-3 staining. For erythroblast analysis as previously described [13].
###end p 22
###begin title 23
Results
###end title 23
###begin p 24
###xml 207 212 207 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 346 350 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Wernig1">[12]</xref>
###xml 352 356 352 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Lacout1">[14]</xref>
###xml 547 552 547 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 730 734 730 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Wernig1">[12]</xref>
###xml 1019 1025 1011 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g001">Fig. 1</xref>
###xml 19 24 <span type="species:ncbi:10090">mouse</span>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 289 294 <span type="species:ncbi:9606">human</span>
###xml 598 602 <span type="species:ncbi:10090">mice</span>
###xml 675 680 <span type="species:ncbi:10090">mouse</span>
###xml 740 744 <span type="species:ncbi:10090">mice</span>
###xml 825 829 <span type="species:ncbi:10090">mice</span>
###xml 897 901 <span type="species:ncbi:10090">mice</span>
###xml 917 921 <span type="species:ncbi:10090">mice</span>
###xml 1153 1157 <span type="species:ncbi:10090">mice</span>
A well-established mouse model that closely phenocopies human PV was used to test the role of the spleen in PV. Briefly, adoptive transfer of retro virally transduced bone marrow cells containing mutant JAK2V617F-GFP into lethally irradiated mice leads to a disease that closely resembles human PV, including elevated hematocrit and splenomegaly [12], [14]. In order to test the role of the spleen in V617F-driven PV, therefore, we removed the spleen (SPL) or performed a sham operation (SH) 2 weeks prior to a bone marrow transplant (BMT) of JAK2V617F-containing bone marrow cells. Two strains of mice, C57Bl6 and Balb/c, were used in order to obtain generalizable data for mouse models that differ slightly in disease phenotype [12]. All mice tolerated surgery and the BMT procedure without complication. While SH operated mice rapidly develop PV (Hct = 61.3+/-3.6 in Balb/c and 73+/-2.6% in B6 mice), SPL operated mice fail to develop PV over the 7 week observation period (45.8+/-1.4 and 49.8+/-1.9%, respectively; Fig. 1). As would be expected after removing the splenic depot of red blood cells (RBCs), RBC mass was higher in SH operated than SPL mice, although this did not reach statistical significance (sTab1). Reductions in other amplified hematopoietic lineages such as white blood cells (WBCs) and platelets were also observed in the SPL cohort, although these were clearly not normalized (sTab1).
###end p 24
###begin title 25
###xml 25 30 25 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
Splenectomy prevents Jak2V617F -driven polycythemia in mice.
###end title 25
###begin p 26
###xml 292 297 249 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 30 34 <span type="species:ncbi:10090">mice</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 424 428 <span type="species:ncbi:10090">mice</span>
###xml 572 576 <span type="species:ncbi:10090">mice</span>
(A) 6 week old female C57Bl/6 mice underwent splenectomy (SPL, blacksquare, square, filled) or sham (SH, square) operations. (B) 6 week old female Balb/c mice underwent splenectomy (SPL, diamond) or sham (SH, lozenge) operations. Followed by 2 week recovery, irradiation and injection of Jak2V617F -transduced bone marrow cells from congenic donors. Hematocrit was measured weekly until disease was maximal in sham-operated mice (n = 12/group, error bars indicate SD). Open symbols = sham operated; filled symbols = splenectomy. * indicates p<0.05 compared to SH operated mice.
###end p 26
###begin p 27
###xml 106 111 106 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 115 116 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 151 160 151 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g002">Figure 2A</xref>
###xml 233 238 233 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 242 243 242 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 273 278 273 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 359 365 359 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g002">Fig 2B</xref>
###xml 393 398 393 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 487 493 487 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g002">Fig 2C</xref>
###xml 538 543 538 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 1190 1195 1190 1195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 178 182 <span type="species:ncbi:10090">mice</span>
###xml 353 357 <span type="species:ncbi:10090">mice</span>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
###xml 713 717 <span type="species:ncbi:10090">mice</span>
###xml 1004 1008 <span type="species:ncbi:10090">mice</span>
###xml 1270 1274 <span type="species:ncbi:10090">mice</span>
In order to rule out the possibility that a lack of PV is due to BMT engraftment failure, we measured JAK2V617F-GFP+ cells in bone marrow. As shown in Figure 2A, both SH and SPL mice harbor similar, large (15-25%) populations of JAK2V617F-GFP+ cells. Similarly, mutant JAK2V617F DNA in the bone marrow is readily detectable and similar in SH versus SPL mice (Fig 2B). Surprisingly, mutant JAK2V617F allele burden in the blood of splenectomized mice is more than double the burden in SH (Fig 2C). This implies that the total burden of JAK2V617F disease is comparable in SH and SPL mice because the diseased spleen, approximately 600-800 mg, primarily harbors mutant erythroblasts (sTab1). Lower hematocrits in SPL mice most likely reflects underproduction of RBCs, as opposed to increased turnover, as indicated by normal peripheral blood smears, LDH and bilirubin levels, and no evidence of hemosiderin in macrophages (data not shown). Finally, evidence of extramedullary hematopoiesis is lacking in SPL mice, as indicated by normal liver weights, equivalently low liver erythroid progenitor cells (sTab1), and no pathologic enlargement of lymph nodes by visual inspection. Thus, while JAK2V617F mutation-bearing cells readily engraft into the bone marrows of recipient mice, the lack of a spleen severely impairs or prevents PV.
###end p 27
###begin title 28
###xml 31 36 31 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
Splenectomy does not alter Jak2V617F disease burden in bone marrow.
###end title 28
###begin p 29
###xml 49 54 49 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g001">Fig 1</xref>
###xml 229 234 229 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
At the termination of the SPL-BMT study shown in Fig 1, bone marrow cells were harvested and live, GFP+ cells were analyzed by flow cytometry (A) DNA from bone marrow aspirates (B) and blood (C) was also prepared and PCR for Jak2V617F allele was performed. *p<0.01 compared to SH operated mice (n = 6 mice/group in all groups).
###end p 29
###begin p 30
###xml 50 55 50 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 96 101 96 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g003">Fig 3</xref>
###xml 142 147 142 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 285 290 285 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g003">Fig 3</xref>
###xml 439 444 439 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 481 486 481 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 678 683 678 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g003">Fig 3</xref>
###xml 826 831 826 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g003">Fig 3</xref>
###xml 884 889 884 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 974 979 974 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 1096 1101 1096 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 1195 1200 1195 1200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 327 331 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 512 516 <span type="species:ncbi:10090">mice</span>
###xml 672 676 <span type="species:ncbi:10090">mice</span>
###xml 711 715 <span type="species:ncbi:10090">mice</span>
Histological analysis further confirms active JAK2V617F-driven disease in both SH and SPL mice (Fig 3). Typically, mice which receive the JAK2V617F BMT sequentially develop myeloid and erythroid hypercellularity, increased numbers of megakaryocytes and reticulin fibrosis. As shown in Fig 3, compared to age-matched, normal B6 mice, megakaryocytosis and reticulin fibrosis is readily identifiable in the bone marrow of both SH and SPL JAK2V617F- transplanted mice. Progressive JAK2V617F-driven disease in Balb/c mice, as exemplified by new bone formation (osteosclerosis) and extensive, nonlinear reticulin fibrosis is similarly seen in the bone marrow of both SH and SPL mice (Fig 3, right panels). Similarly, mice which undergo SPL after BMT still show hypercellularity and reticulin fibrosis despite normalized hematocrit (Fig 3, lower panels). These findings demonstrate that JAK2V617F-driven, elevated hematocrit (polycythemia) can be pathologically independent of JAK2V617F-driven fibrosis/osteosclerosis in bone marrow. This would suggest that splenectomy, while effective at reducing JAK2V617F-driven pathology in blood (elevated hematocrit), does not alter the pathologic course of JAK2V617F-driven PV in bone marrow.
###end p 30
###begin title 31
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Pathologic fibrosis and osteosclerosis are equivalent in polycythemic and splenectomized, normocythemic mice.
###end title 31
###begin p 32
###xml 72 76 <span type="species:ncbi:10090">mice</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 349 353 <span type="species:ncbi:10090">mice</span>
###xml 474 478 <span type="species:ncbi:10090">mice</span>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
A. In the SPL-->BMT experiment, histology was performed on tissues from mice approximately 9-10 weeks after SH or SPL. Bone marrow histology shows increased cellularity, prominent megakaryocytes (arrowheads) and reticulin fibrosis (thin arrows in lower panels) in both SH and SPL groups of mice compared to age-matched normal bone marrow. In Balb/c mice, extensive new bone formation (osteosclerosis, aqua arrows) and reticulin fibrosis are found equally in both SH and SPL mice 6 weeks after transplant. B. Splenectomy after V617F-driven PV occurs results in similar hypercellularity (top H & E staining) and reticulin fibrosis in SH and SPL operated mice.
###end p 32
###begin p 33
###xml 158 163 158 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 387 393 387 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g004">Fig. 4</xref>
###xml 650 653 646 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;10</sup>
###xml 886 891 882 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g004">Fig 4</xref>
###xml 1259 1264 1255 1260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 1370 1375 1366 1371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
###xml 455 459 <span type="species:ncbi:10090">mice</span>
###xml 601 605 <span type="species:ncbi:10090">mice</span>
###xml 725 729 <span type="species:ncbi:10090">mice</span>
###xml 783 787 <span type="species:ncbi:10090">mice</span>
###xml 830 834 <span type="species:ncbi:10090">mice</span>
###xml 1028 1032 <span type="species:ncbi:10090">mice</span>
###xml 1169 1173 <span type="species:ncbi:10090">mice</span>
If an intact spleen is required for establishment of PV, is it required for maintenance of PV? In order to test this, PV burdened mice were generated via JAK2V617F-GFP BMT and the spleens were removed posttransplant 4 weeks later. In order to assure that PV was at equilibrium, mice were not operated on until hematocrits had uniformly reached maximal, stable values (>64%). As shown in Fig. 4, SH operation has no effect on hematocrit in polycythemic B6 mice, which maintain high hematocrit levels (final 67.4+/-3.2%). In contrast, SPL results in a rapid decline in hematocrit to normal levels in B6 mice where they are maintained (40.6+/-3.7%, p<10-10). Normalization of hematocrit was observed in 3 separate cohorts of B6 mice at similar rates of descent (data not shown). Balb/c mice responded similarly, although SH operated mice also demonstrated a slight lowering of hematocrit (Fig 4, right). Similar to what is observed when SPL precedes BMT; mutant, GFP+ cells are easily measured in the bone marrow of splenectomized mice (sTab2). Moreover, and as has been well described in prior reports, splenectomy has no effect on hematocrit in normal, non polycythemic mice (data not shown). In conclusion, an intact spleen is required for maintenance of JAK2V617F-driven PV. We postulate that the spleen provides either a required niche or a required factor(s) for JAK2V617F-expressing hematopoietic cells to maintain the high hematocrit that characterizes PV.
###end p 33
###begin title 34
###xml 41 46 41 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
Splenectomy normalizes hematocrit in Jak2V617F -driven polycythemia vera.
###end title 34
###begin p 35
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
B6 (left) and Balb/c (right) mice were injected with V617F-transduced, congenic bone marrow cells and allowed to develop polycythemia. After sham (SH, square) or splenectomy (SPL, blacksquare, square, filled) operations, mice were followed weekly and hematocrit measured by spun hematocrit. * p<0.05 compared to SH operated mice.
###end p 35
###begin p 36
###xml 112 117 112 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 373 377 373 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Raff1">[15]</xref>
###xml 492 496 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-McDonald1">[16]</xref>
###xml 552 557 552 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 689 694 689 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 417 421 <span type="species:ncbi:10090">mice</span>
Is a spleen required for polycythemia generally? Polycythemia can result either from a hormone-independent, JAK2V617F-driven primary process, or a hormone (Epo)-dependent secondary process. It is clear from prior reports that the spleen is not required for maintenance of hematocrit, nor for regeneration of all hematopoietic lineages following bone marrow transplantation [15]. More specifically, splenectomy in CD1 mice only blunts, but does not prevent secondary, Epo-induced polycythemia [16]. This presents a paradox, because cell autonomous, JAK2V617F-driven "true" PV requires a spleen, but cell non-autonomous, or secondary polycythemia may not. Thus, erythropoiesis driven by JAK2V617F results in polycythemia that requires a spleen, while erythropoiesis driven by wild type JAK2 does not.
###end p 36
###begin p 37
###xml 548 552 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Mathur1">[17]</xref>
###xml 658 663 649 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 815 820 806 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 994 1000 985 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g005">Fig. 5</xref>
###xml 1200 1205 1183 1188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 1380 1385 1363 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007286-g005">Fig 5</xref>
###xml 1779 1784 1758 1763 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 190 195 <span type="species:ncbi:9606">human</span>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
###xml 320 325 <span type="species:ncbi:9606">human</span>
###xml 543 547 <span type="species:ncbi:10090">mice</span>
###xml 633 638 <span type="species:ncbi:9606">human</span>
###xml 851 855 <span type="species:ncbi:10090">mice</span>
###xml 1021 1025 <span type="species:ncbi:10090">mice</span>
###xml 1221 1225 <span type="species:ncbi:10090">mice</span>
###xml 1374 1378 <span type="species:ncbi:10090">mice</span>
###xml 1453 1457 <span type="species:ncbi:10090">mice</span>
In order to investigate this more fully, we tested the effects of splenectomy on Epo-induced, secondary polycythemia in 2 strains of mice. We first optimized a dosing regimen of recombinant human erythropoietin (Aranesptrade mark) that induces polycythemia in mice, and closely recapitulates the pathologic hallmarks of human PV. Administration of Aranesp 3 times over 7 days (qOD), for example, uniformly results in polycythemia (hct>65%), reticulocytosis (>25% reticulocytes) and splenomegaly (>600 mg, normal = 80 mg) in both B6 and Balb/c mice [17]. Thus, this Epo-stimulated model offers many of the major anatomic hallmarks of human PV without the JAK2V617F mutation. We used this model of secondary polycythemia to investigate the role of the spleen in secondary, Epo-driven compared to cell autonomous, JAK2V617F-driven PV. Both B6 and Balb/c mice underwent SH or SPL operations, were allowed to recuperate for 2 weeks, and Aranesp was administered three times over 1 week. As shown in Fig. 5, both B6 and Balb/c mice readily develop polycythemia (67.5+/-1.7 and 66+/-0.8%) and splenomegaly (624+/-46 and 607+/-32 mg) after SH operation. Similarly, but in contrast to what is observed in JAK2V617F-driven PV, SPL mice also develop polycythemia to a level that is more than 80% of the increase seen from normal, and 90-92% of the total hematocrit seen in SH operated mice (Fig 5). Thus, a robust polycythemic phenotype develops in splenectomized mice in response to wild type (Epo-->Epo receptor-->Jak2) signaling. Furthermore, chronic injection of Aranesp over weeks, inducing persistent polycythemia and splenomegaly, fails to induce fibrosis in bone marrow or spleen (data not shown). Thus, the pathology of Epo-induced, secondary polycythemia contrasts sharply to JAK2V617F-driven PV, which requires an intact spleen and leads to fibrosis/osteosclerosis in hematopoietic tissues.
###end p 37
###begin title 38
###xml 63 67 <span type="species:ncbi:10090">mice</span>
Secondary (Epo-stimulated) polycythemia develops in SH and SPL mice.
###end title 38
###begin p 39
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
Eight week old B6 and Balb/c mice (n = 4/group) underwent SH or SPL operations, and 2 weeks later erythropoietin was administered for 7 days. Both SH and SPL mice develop significant polycythemia.
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 314 319 314 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 548 553 548 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 888 893 888 893 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 1167 1172 1167 1172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 1292 1296 1292 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Morgan1">[18]</xref>
###xml 1297 1301 1297 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Larsen1">[20]</xref>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 1250 1258 <span type="species:ncbi:9606">patients</span>
The observed differences between the role of the spleen in primary versus secondary polycythemia could be explained if 2 independent pathologic processes lead to elevation in hematocrit and bone marrow fibrosis, respectively. In the first, the spleen provides either a required factor or an anatomic niche for JAK2V617F-expressing cells, leading to erythrocytosis and increased hematocrit. These could be distinguished if it were possible to induce hematocrit elevation in splenic extracts versus splenic re-transplantation into splenectomized JAK2V617F-harboring mice. These mechanisms are not mutually exclusive, however, if the spleen elaborates a critical factor (Epo) in the PV context, for example, thus providing both ligand stimulation a pathogenic niche. In the second process, one or multiple of the amplified myeloid lineages (red cell, white cell, or platelet-forming) of JAK2V617F-expressing cells mediate fibrosis and osteosclerosis in the bone marrow, and this process occurs independently of elevations in hematocrit. If indeed essential thrombocythemia (ET), PV and primary myelofibrosis (PMF) represent a continuum of one disease that differ in JAK2V617F gene dosage, then it will be critically important to know the gene dosage in patients prior to considering splenectomy [18]-[20]. This consideration would be important because SPL, although effective in lowering hematocrit, could also potentially alter disease progression the bone marrow.
###end p 41
###begin p 42
###xml 174 179 174 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 854 858 854 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-deHaan1">[21]</xref>
###xml 572 576 <span type="species:ncbi:10090">mice</span>
###xml 724 728 <span type="species:ncbi:10090">mice</span>
###xml 1495 1499 <span type="species:ncbi:10090">mice</span>
###xml 1683 1687 <span type="species:ncbi:10090">mice</span>
An alternative possibility is that hematopoietic competition in the bone marrow space, in the absence of a spleen, prevents erythroid expansion specifically. That is, if JAK2V617F -expressing erythroid, myeloid and megakaryocytic lineages in PV compete in the marrow space, then splenectomy could limit pathologic expansion. In contrast, pathologic stimulation of a single lineage of cells, via Epo for example, results in a homogeneously (erythroid) hyper cellular bone marrow that is sufficient to maintain elevated hematocrit. This model has been intensively tested in mice via high-dose, ligand-stimulation (G-CSF, Epo) competition experiments. In these experiments, co-administration of Epo and G-CSF to splenectomized mice only modestly reduces late stage granulocyte and erythrocyte lineages, respectively, and SCF prevents this mutual inhibition [21]. Thus, even maximal myeloid-expanding ligand stimulation has only a modest, and not preventative, effect on erythroid expansion even in the absence of a spleen. Further studies could test whether the arrest of erythroid expansion after SPL in PV is a result of competition between multiple hematopoietic lineages in a restricted space. Noting that the pathogenesis of myelofibrosis and erythrocytosis can be dissociated by removal of the spleen, one hypothesis is that the spleen provides a niche for specific populations of endogenous erythroid colony-forming cells (EECs). We were not able to grow EECs from V617F-transplanted Balb/c mice. Thus, additional studies might help to determine whether differences in EEC numbers or proliferation explain normal versus polycythemic phenotypes observed in SPL versus SH operated mice, respectively.
###end p 42
###begin p 43
###xml 722 728 <span type="species:ncbi:10090">murine</span>
###xml 762 767 <span type="species:ncbi:10090">mouse</span>
We recognize that secondary, Epo (Aranesp)-driven erythrocytosis represents a stronger phenotype than V617F-driven polycythemia due to the shorter time required for progression of disease (7 versus 14-28 days, respectively). Thus, a stronger erythropoietic drive has the potential to explain the presence (Epo) or absence (V617F) of polycythemia following SPL in these 2 models. Nonetheless, these 2 models achieve similar, maximal and stable levels of hematocrit (65%). Thus, if viewed in terms of maximal polycythemia observed, the effect of SPL has a marked, curative consequence in the mutant model, while only blunting the phenotype of Epo-induced polycythemia. Additional experiments, such as administering low-dose murine Epo chronically, or generating a mouse expressing low levels of Epo transgenically, would further address whether SPL has a similar effect of a similar time frame in secondary (Epo) versus mutant-driven (V617F) polycythemia.
###end p 43
###begin p 44
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Wernig1">[12]</xref>
###xml 897 901 897 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Wernig1">[12]</xref>
###xml 1053 1057 1053 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Wernig1">[12]</xref>
###xml 1108 1112 1108 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Xing1">[19]</xref>
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 658 662 <span type="species:ncbi:10090">mice</span>
###xml 731 735 <span type="species:ncbi:10090">mice</span>
###xml 787 791 <span type="species:ncbi:10090">mice</span>
###xml 1103 1107 <span type="species:ncbi:10090">mice</span>
Two strains of mice were used in these experiments in order to reduce the likelihood that any effects we measured were due to strain variations. Marked strain variations, similar to what has been reported, were observed with respect to bone marrow and spleen myelofibrosis [12]. For example, at 6 weeks of age the majority of Balb/c mice harbor myelofibrosis in the bone marrow, while none of the C57Bl6 (B6) mice show this abnormality (data not shown). This difference is observed despite using identical titers of V617F-containing virus, and despite similar levels of maximal hematocrit. Later, by approximately 12-14 weeks of age, more than 50% of the B6 mice show reticulin fibrosis in the bone marrow. In comparison to Balb/c mice, which show marked myelofibrosis at this stage, B6 mice show a more modest phenotype. This variable myelofibrotic phenotype resembles that seen in prior reports [12]. These observations agree with prior hypotheses, which suggest that unknown genetic modifiers result in a heterogeneous phenotype both between strains [12] and even within a single, transgenic line of mice [19].
###end p 44
###begin p 45
###xml 302 307 302 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 511 515 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Messinezy1">[22]</xref>
###xml 525 530 525 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 660 664 660 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Hsieh1">[23]</xref>
###xml 704 706 704 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sup>
###xml 854 858 854 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Agool1">[24]</xref>
###xml 1653 1658 1653 1658 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 95 101 <span type="species:ncbi:9606">humans</span>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
###xml 235 240 <span type="species:ncbi:9606">human</span>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
###xml 454 462 <span type="species:ncbi:9606">patients</span>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
###xml 745 753 <span type="species:ncbi:9606">patients</span>
###xml 772 780 <span type="species:ncbi:9606">patients</span>
###xml 913 921 <span type="species:ncbi:9606">patients</span>
###xml 1240 1248 <span type="species:ncbi:9606">patients</span>
###xml 1276 1284 <span type="species:ncbi:9606">patients</span>
###xml 1417 1422 <span type="species:ncbi:9606">human</span>
###xml 1562 1570 <span type="species:ncbi:9606">patients</span>
The amount of EMH that takes place in the spleen is likely to be different in mice (high) than humans (modest). Nonetheless, our finding that SPL normalizes only the erythroid lineage in mice allows at least a theoretical extension to human PV. If, for example, the spleen is required for primary, JAK2V617F-driven PV, then all patients should have splenomegaly or at least EMH in the spleen. By clinical examination and ultrasound, the vast majority of patients with PV do indeed have evidence of splenomegaly [22]. The JAK2V617F mutation can indeed be detected in the spleen as well as BM in patients with PV, and clonality suggests an origin in bone marrow [23]. Furthermore, noninvasive imaging with 18F-FLT PET shows evidence of EMH in all patients with PV, although patients with end-stage splenic fibrosis may not be expected to have this finding [24]. We are, furthermore, not aware of any cases of PV in patients who were asplenic prior to the onset of disease, although absence of this data cannot constitute proof. In order to clinically test the hypothesis that the spleen is required for PV, it will be necessary to first understand and control the abnormal rheology of blood, as well as the susceptibility to infections in PV patients undergoing splenectomy. If patients with PV can be effectively treated, spleen size is reduced, and this treatment lowers surgical risk, then the role of the spleen in human PV could be tested directly. We predict that, unlike other malignant conditions (CML) that are accompanied by splenomegaly, splenectomy in patients with PV will reduce hematocrit to normal levels. The consequences of residual JAK2V617F burden in the bone marrow will be important to characterize further.
###end p 45
###begin p 46
###xml 57 62 57 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 343 347 343 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Tefferi1">[25]</xref>
###xml 536 541 536 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 649 654 649 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 733 738 733 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 883 887 883 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Cadili1">[26]</xref>
###xml 929 934 929 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 1039 1043 1039 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007286-Scott1">[27]</xref>
###xml 1100 1105 1100 1105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 1163 1168 1163 1168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 1030 1035 <span type="species:ncbi:9606">human</span>
###xml 1260 1265 <span type="species:ncbi:9606">human</span>
Despite the recent and remarkable discovery that the JAK2V617F mutation plays a critically important role in the development of PV, much remains unknown about its pathogenesis. Others and we have designed specific inhibitors of JAK2 that may be useful therapies for PV, although their benefit over current treatment remains to be demonstrated [25]. Our data predict that spleen size itself will offer a highly sensitive, noninvasive measurement of disease, and that splenectomy will prevent the hematocrit-elevating consequences of JAK2V617F-associated disease. We propose that a cure for PV, however, will require reducing or ablating residual JAK2V617F burden in the bone marrow. Interestingly, our finding that splenectomy in JAK2V617F-driven, PV improves erythroid neoplasia sharply contrasts sharply to studies which suggest that splenectomy may accelerate frank carcinogenesis [26]. Our observations are limited to the JAK2V617F mutation, and cannot necessarily be extrapolated to the remaining 5% of mutations described in human PV [27]. Finally, these data show that the spleen-dependent JAK2V617F-driven polycythemia is pathologically independent of JAK2V617F-associated reticulin fibrosis and osteosclerosis in bone marrow. The role of the spleen in human PV, as well as other, clinically untested splenomegaly-associated diseases remains unknown.
###end p 46
###begin title 47
Supporting Information
###end title 47
###begin p 48
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 319 325 <span type="species:ncbi:10090">murine</span>
Hematopoietic and anatomic changes in mice who first underwent surgery (splenectomy or sham) and then secondarily received V617F-containing cells via bone marrow transplant. Surgery was performed, and then 2 weeks after surgery mice were transplanted with congenic bone marrow cells that were transduced with the V617F murine gene construct. After 7 weeks, analysis of cellularlity, V617F mutation positive (GFP+), erythroid (Ter119+) cells, complete blood count and organ size was performed. Vacant data in SPL columns are due to splenectomy performed at the start of treatment.
###end p 48
###begin p 49
(0.14 MB PDF)
###end p 49
###begin p 50
Click here for additional data file.
###end p 50
###begin p 51
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 145 149 <span type="species:ncbi:10090">Mice</span>
Hematopoietic changes in mice who were transplanted with V617F-transduced bone marrow, and secondarily underwent splenectomy or sham operations. Mice were first irradiated, transplanted with congenic bone marrow cells harboring the V617F mutation, and then surgery was performed 4 weeks later (V617FBMT-Surgery). After 7 weeks, analysis of cellularlity, V617F mutation positive (GFP+), erythroid (Ter119+) cells, complete blood count was performed.
###end p 51
###begin p 52
(0.13 MB PDF)
###end p 52
###begin p 53
Click here for additional data file.
###end p 53
###begin p 54
We thank Sada Breegi for help with animal laboratory resource allocation.
###end p 54
###begin title 55
References
###end title 55
###begin article-title 56
Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Cancer, 1984.
###end article-title 56
###begin article-title 57
Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia.
###end article-title 57
###begin article-title 58
Modern treatment strategies in polycythemia vera.
###end article-title 58
###begin article-title 59
Surgery in Polycythemia Vera.
###end article-title 59
###begin article-title 60
Splenectomy for massive splenomegaly of polycythemia vera.
###end article-title 60
###begin article-title 61
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
###end article-title 61
###begin article-title 62
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
###end article-title 62
###begin article-title 63
###xml 49 54 <span type="species:ncbi:9606">human</span>
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
###end article-title 63
###begin article-title 64
A gain-of-function mutation of JAK2 in myeloproliferative disorders.
###end article-title 64
###begin article-title 65
Identification of an acquired Jak2 mutation in polycythemia vera.
###end article-title 65
###begin article-title 66
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
###end article-title 66
###begin article-title 67
###xml 99 105 <span type="species:ncbi:10090">murine</span>
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
###end article-title 67
###begin article-title 68
Suppression of Fas-FasL co expression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo.
###end article-title 68
###begin article-title 69
###xml 24 30 <span type="species:ncbi:10090">murine</span>
###xml 74 79 <span type="species:ncbi:9606">human</span>
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.
###end article-title 69
###begin article-title 70
Splenectomy does not enhance engraftment of DLA-nonidentical marrow transplants.
###end article-title 70
###begin article-title 71
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Large, chronic doses of erythropoietin cause thrombocytopenia in mice.
###end article-title 71
###begin article-title 72
###xml 56 60 <span type="species:ncbi:10090">mice</span>
An inhibitor of Janus kinase 2 prevents polycythemia in mice.
###end article-title 72
###begin article-title 73
A role for Jak2 mutations in myeloproliferative diseases.
###end article-title 73
###begin article-title 74
###xml 29 34 29 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</sup>
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.
###end article-title 74
###begin article-title 75
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype.
###end article-title 75
###begin article-title 76
###xml 21 27 <span type="species:ncbi:10090">murine</span>
Mutual inhibition of murine erythropoiesis and granulopoiesis during combined erythropoietin, granulocyte colony-stimulating factor, and stem cell factor administration: in vivo interactions and dose-response surfaces.
###end article-title 76
###begin article-title 77
Spleen sizing by ultrasound in polycythemia and thrombocythaemia; comparison with SPECT.
###end article-title 77
###begin article-title 78
The role of Janus kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.
###end article-title 78
###begin article-title 79
18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment.
###end article-title 79
###begin article-title 80
Polycythemia vera: a comprehensive review and clinical recommendations.
###end article-title 80
###begin article-title 81
Complications of splenectomy.
###end article-title 81
###begin article-title 82
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
###end article-title 82
###begin p 83
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: All of the authors have had an affiliation with Merck, and this does not alter their adherence to the PLOS policies on sharing data and materials as detailed in the policy statement.
###end p 83
###begin p 84
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: All funding was from Merck Research Laboratories. The funders, Merck Research Laboratories (MRL), employed the investigators/authors who designed the study, collected the data, analyzed the data and prepared the manuscript: MRL played a role (supported decision) in the decision to publish the manuscript.
###end p 84

